Valuation: Indivior PLC

Market Cap 4.58B 3.96B 3.7B 3.39B 6.39B 436B 6.49B 43.42B 17.04B 219B 17.2B 16.83B 722B P/E 2026 *
10.4x
P/E 2027 * 9.46x
Enterprise Value 4.64B 4.01B 3.74B 3.44B 6.46B 441B 6.56B 43.93B 17.24B 221B 17.41B 17.03B 731B EV / Sales 2026 *
3.49x
EV / Sales 2027 * 3.07x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-1.64% - - 4.58B
-0.52%+3.21%+89.52%+127.32% 1,057B
+0.88%+1.13%+49.56%+49.69% 625B
+0.89%-1.95%+24.23%+64.44% 435B
+0.71%+3.87%+49.07%+37.85% 363B
+0.64%-0.49%+33.94%+40.01% 296B
+0.39%-5.83%+8.92%+7.85% 249B
+1.51%+6.69%+42.58%+57.57% 222B
+3.92%-0.46%-5.56%-52.32% 209B
+1.80%+2.30%+11.56%+66.35% 165B
Average +0.84%+0.87%+33.76%+44.31% 402.31B
Weighted average by Cap. +0.65%+1.22%+48.72%+64.63%

Financials

2026 *2027 *
Net sales 1.33B 1.15B 1.07B 983M 1.85B 126B 1.88B 12.58B 4.94B 63.31B 4.98B 4.87B 209B 1.36B 1.18B 1.1B 1.01B 1.9B 130B 1.93B 12.91B 5.07B 64.97B 5.11B 5B 215B
Net income 467M 404M 377M 346M 651M 44.45B 661M 4.43B 1.74B 22.28B 1.75B 1.72B 73.65B 503M 435M 406M 372M 700M 47.83B 712M 4.76B 1.87B 23.97B 1.89B 1.85B 79.25B
Net Debt 54.5M 47.14M 44.02M 40.39M 75.96M 5.19B 77.17M 517M 203M 2.6B 205M 200M 8.59B -403M -349M -326M -299M -562M -38.39B -571M -3.82B -1.5B -19.24B -1.51B -1.48B -63.62B
Logo Indivior PLC
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-